Severe Acute Hepatocellular Injury Attributed to OxyELITE Pro: A Case Series by Heidemann, Lauren A. et al.
Severe Acute Hepatocellular Injury Attributed to OxyELITE Pro: 
A Case Series
Lauren A Heidemann, M.D.1, Victor J Navarro, M.D.2, Jawad Ahmad, M.D.3, Paul H. Hayashi, 
M.D.4, Andrew Stolz, M.D.5, David E. Kleiner, M.D.6, and Robert J. Fontana, M.D.1 on behalf 
of the DILIN Investigators
Lauren A Heidemann: lheidema@med.umich.edu; Victor J Navarro: NavarroV@einstein.edu; Jawad Ahmad: 
jawad.ahmad@mountsinai.org; Paul H. Hayashi: paul_hayashi@med.unc.edu; Andrew Stolz: astolz@usc.edu; David E. 
Kleiner: kleiner@mail.nih.gov
1Department of Internal Medicine, University of Michigan Medical Center, Ann Arbor, MI
2Department of Medicine, Einstein Healthcare Network, Philadelphia, PA
3Department of Medicine, Icahn School of Medicine at Mount Sinai Medical Center, New York, NY
4University of North Carolina, Chapel Hill, NC
5University of Southern California, Los Angeles, CA
6Laboratory of Pathology, National Cancer Institute, National Institutes of Health, Bethesda, MD
Abstract
BACKGROUND/AIMS—Herbal and dietary supplement (HDS) hepatotoxicity is increasingly 
being reported in the United States. This case series describes the presenting clinical features and 
outcomes of 7 patients with liver injury attributed to OxyELITE Pro enrolled in the Drug Induced 
Liver Injury Network (DILIN) study.
METHODS—The 6 month outcomes of patients with hepatotoxicity attributed to OxyELITE Pro 
enrolled in the DILIN prospective registry between 2004 and 2015 are presented.
RESULTS—Six of the 7 patients (86%) presented in 2013 with symptoms of hepatitis and acute 
hepatocellular injury. The median duration of OxyELITE Pro use was 18 weeks (range: 5 to 102 
weeks). Median age was 36 years (range: 28 to 62), 86% were female, and 43% were Asian. One 
patient had rash, none had eosinophilia and 3 had antinuclear antibody reactivity. The median peak 
ALT was 2242 U/L, alkaline phosphatase 284 U/L and bilirubin 15.0 mg/dL. Six patients (86%) 
were hospitalized, 3 developed acute liver failure and 2 underwent liver transplantation. DILIN 
causality scores for OxyELITE Pro were definite in 1, highly likely in 3, probable in 2, and 
possible in 1. Four of the 5 patients without liver transplant recovered completely within 6 months 
while one patient had mild residual ALT elevations.
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CONCLUSIONS—Seven cases of severe acute hepatocellular injury attributed to OxyELITE Pro 
are reported. These results reinforce the need to assess for HDS supplement use in patients 
presenting with unexplained acute hepatitis and point to the need for additional regulatory 
oversight of HDS products.
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hepatotoxicity; herbal and dietary supplement; drug-induced liver injury
Introduction
An estimated 50 to 60% of adult Americans ingest an herbal or dietary supplement (HDS) 
on a regular basis for a variety of touted health benefits (1, 2). Although HDS products are 
perceived to be safe and “natural”, they do not undergo routine efficacy or safety testing. A 
recent study reported that at least 23,000 emergency department visits in the United States 
each year are attributed to adverse events from dietary supplements (3). Despite this, the 
Food and Drug Administration (FDA) has limited authority to regulate the manufacturing 
and content of HDS products (4).
OxyELITE Pro (USP Labs, Dallas, TX) is a multi-ingredient nutritional supplement used by 
many individuals as a weight-loss and energy-enhancing aid (5). In mid to late 2013, over 40 
cases of severe acute hepatitis and liver failure were linked to the use of the “Super Thermo” 
formulation of OxyELITE Pro, primarily amongst individuals residing in Hawaii (5–8). The 
etiology and risk factors for hepatotoxicity amongst these patients remain under 
investigation. However, the sudden outbreak followed shortly after a major modification of 
the components of OxyELITE Pro with the addition of aegeline, a constituent of the native 
Ayurvedic herbal product made from the bark of the bael tree (Aele marmelos). The product 
added to OxyELITE Pro, however, had been synthesized by a manufacturer in China and its 
purity, safety and relationship to the natural herbal product was not clear.
Before, during and after the outbreak of liver injury attributed to OxyELITE Pro, the Drug 
Induced Liver Injury Network (DILIN) had been conducting a prospective multicenter study 
of the etiologies and outcomes of patients who developed liver injury due to ingestion of 
drugs and HDS products in the United States (9,10). Over the course of DILIN study, the 
proportion of cases attributed to various HDS products including body building agents and 
weight loss products increased markedly, from 7% in 2004–2006 to 20% since 2012 (11). 
Among the 246 adjudicated cases of DILI attributed to HDS products, 7 were considered to 
be due to OxyELITE Pro, 6 of which presented during mid-to-late 2013. The aim of the 
current study was to describe the presenting features, clinical course and outcomes of 7 
patients enrolled in the DILIN prospective study with liver injury attributed to OxyELITE 
Pro.
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Methods
DILIN prospective study
The protocol for this multicenter observational study was approved by the Institutional 
Review Boards at each clinical site and all enrolled subjects provided written informed 
consent. Liver injury onset was defined as the first date after a subject taking any medication 
or HDS product met the predefined laboratory criteria for study entry. Specifically, all 
subjects had to meet one of the following laboratory criteria on 2 consecutive blood draws: 
(1) a serum aspartate aminotransferase (AST) or alanine aminotransferase (ALT) level that 
exceeded 5 times the upper limit of normal (ULN) (or 5 times a pretreatment baseline value 
if abnormal); (2) a serum alkaline phosphatase (Alk P) that exceeded 2 times the ULN (or 2 
times the pretreatment value if abnormal); or (3) a total bilirubin of 2.5 mg/dL or greater, or 
an international normalized ratio (INR) greater than 1.5 accompanied by an enzyme 
elevation. To qualify for enrollment, study participants had to be enrolled within 6 months of 
onset.
A detailed medical history was obtained at the enrollment study visit and medical records 
were retrieved and relevant information was extracted. Additional laboratory and 
radiological testing were performed if necessary to more fully characterize the event and 
exclude competing etiologies. Specifically, testing for hepatitis A, B, C, HIV, autoantibodies, 
CMV, and EBV infection was obtained in all subjects and serum was stored in a sample 
repository for future diagnostic testing and ancillary studies. In this regard, available 
samples were later tested for IgG anti-HEV and, if positive, for IgM anti-HEV as previously 
reported (12). All enrolled patients were asked to return for a follow-up visit at 6 months 
after enrollment, and those with persistent evidence of liver injury at 6 months after onset 
were then asked to return at 12 and 24 months.
The causal relationship between the liver injury episode and the implicated agent(s) was 
evaluated in a standardized fashion by the DILIN Causality Committee (13). A DILIN 
expert opinion causality score varying from 1 (definite: ≥ 95% likelihood), 2 (highly likely: 
75%–94% likelihood), 3 (probable: 50%–74% likelihood), 4 (possible: 25%–49% 
likelihood) to 5 (unlikely: < 25% likelihood) was assigned by consensus agreement of 
committee members. In addition, an updated causality score using the standardized Roussel 
Uclaf Causality Assessment Method (RUCAM) was calculated for each case and implicated 
agent by manuscript authors in 2015 (14). By convention, RUCAM scores are grouped into 
likelihood levels as “excluded” (≤ 0), “unlikely” (1–2), “possible” (3–5), “probable” (6–8) 
and “highly probable” (> 8). In subjects with 2 or more implicated drugs or HDS products, 
an overall causality score was assigned to the case and then a causality score was also 
determined for each individual suspect drug or HDS product.
The pattern of liver injury was categorized based upon the R-ratio which was defined by the 
formula: [ALT/ULN] ÷ [Alk P/ULN]. Cases were considered hepatocellular if R > 5, 
cholestatic if R < 2 and mixed if R 2–5. The severity of the DILI episode was categorized on 
a 5-point scale from mild (1), moderate (2), moderate-hospitalized (3), severe (4), and fatal 
(5), where a fatal score was assigned only if the patient died or underwent liver 
transplantation due to DILI within 6 months of onset (8).
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Liver histopathology
Liver biopsy was not required and was not a component of the DILIN Prospective Study 
protocol; but if a biopsy were done as a part of clinical evaluation and care, a request was 
made for slides to be forwarded to the Laboratory of Pathology, NIH. All available 
specimens were reviewed by a single expert liver histopathologist (DEK) and scored for 
multiple histological features as well as an overall pattern of liver injury as previously 
described (15).
Data collection and statistics
Electronic case report forms (eCRFs) via InForm™ (Oracle Health Solutions, CA) were 
used to capture data in the DILIN prospective study. Data reported here were based on the 
data download from InForm™ in December 2015. Summary statistics were reported as 
median with range for continuous data and frequency with percentage for categorical data. 
SAS 9.4 [SAS Institute, Cary, NC] was used for all statistical analyses.
Results
Between 2004 and 2015, 1596 patients were enrolled in the DILIN prospective study, 7 of 
whom (0.5%) had liver injury attributed to OxyELITE Pro. One case had injury onset in 
2011 and the remaining 6 occurred between May and December 2013. These 7 cases 
represented 2.8% of the 246 adjudicated cases attributed to HDS products and 5.3% of the 
cases enrolled during calendar year 2013.
The demographic, clinical and laboratory features of the 7 patients with liver injury 
attributed to OxyELITE Pro are summarized in Table 1. All 7 patients were adults, the 
median age was 36 years (range 28–62) and 6 (86%) were women. Self-reported race and 
ethnicity indicated that 4 were Caucasian (one being Hispanic) and 3 Asian. While the most 
common reason for taking OxyELITE Pro was weight loss, most patients had a normal body 
mass index, 1 being mildly overweight and only 1 obese. The median duration of OxyELITE 
Pro use before liver injury onset was 18 weeks, but ranged from 5 to 102 weeks. Two 
patients reported taking OxyELITE Pro in the past (before 2013) without ill effects and 1 
patient took the product for 2 years but presented with liver injury 6 months after March 
2013 when the product was modified. Only 1 patient was a moderate drinker and none had a 
history of alcohol abuse or obvious risk factors for viral hepatitis.
On clinical presentation, the pattern of serum enzyme elevations was hepatocellular in all 
patients; the median R ratio being 16 (range 11–107). Initial ALT values were above 1,000 
U/L in 5 patients and averaged 2950 U/L. Initial Alk P values in contrast were typically 
normal (n=2) or only modestly elevated (n=5) in the range of 1.5–3 times ULN. Serum total 
bilirubin values were raised in 6 patients and ranged widely (0.4 to 24.5 mg/dL) and 
averaged 10.9 mg/dL. Immunoallergic features were not prominent; 1 patient had rash, 2 had 
fever, and none had documented peripheral eosinophilia. Autoantibodies were present in 4 
patients but none had other features of autoimmune hepatitis and corticosteroids were used 
in only 1 patient, who had rapidly progressive hepatic failure. Testing for acute HAV, HBV 
and HCV infection was negative in all patients, although one (case #7) appeared to be a 
Heidemann et al. Page 4
Dig Dis Sci. Author manuscript; available in PMC 2017 September 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
chronic carrier of hepatitis B who had a superimposed severe acute liver injury (having 
HBsAg without IgM anti-HBc and no detectable HBV DNA). Tests for acute HEV infection 
were available on 4 patients and were negative in all. Liver imaging was performed in all 
patients and none had evidence of biliary obstruction or hepatic masses.
Causality assessment
Formal causality assessment judged 1 case to be definite, 2 highly likely, 3 probable, and 1 
possible liver injury due to exposure to OxyELITE Pro. (Table 1). Similarly, the RUCAM 
scores varied from 2 to 7, being in the range of unlikely in 1, possible in 4 and probable in 2 
(calculations are shown in Supplementary Table 1). Five patients were taking other 
prescription medications or HDS products that were listed as implicated, but only in case #1 
were these agents considered a more probable cause of the hepatic injury.
Clinical severity and outcomes
The DILIN severity scores included 1 mild, 3 moderate-hospitalized, 1 severe and 2 fatal, 
the latter two undergoing emergency liver transplantation 24 days after clinical presentation. 
Liver histology was available for central review in 3 patients. One patient (Case #2) with a 
percutaneous liver biopsy done 4 days after presentation and at the peak of injury showed a 
cholestatic hepatitis pattern best characterized as acute hepatitis with moderate, 
predominantly lobular inflammation, mild canalicular cholestasis, and scattered eosinophils 
(Figure 1A/1B). Recuts from a single paraffin block from each of the two explants were also 
available for review (Figure 1C/1D). One case showed submassive necrosis with few 
residual viable hepatocytes while the other showed necrosis in zone 1 and 3 with extensive 
bridging necrosis and early regenerative nodule formation. Although plasma cells were 
noted within the infiltrate at transplantation, neither had other features suggestive of 
autoimmune hepatitis. The residual parenchyma in both cases showed prominent cholestasis.
At last follow-up, at 22 and 26 months post-transplant, the 2 patients who underwent liver 
transplantation were doing well and had normal serum bilirubin and liver enzymes. Four of 
the other 5 patients had self-limited hepatitis with full recovery without corticosteroid or 
other specific therapy at month 6 but 1 patient (Case #4) had evidence of mild biochemical 
liver injury at follow-up month 8.
Discussion
These seven generally healthy, middle aged adults developed acute hepatitis after ingesting a 
widely used weight loss, multi-ingredient nutritional product called OxyELITE Pro for as 
short as 5 weeks to as long as 2 years. Outcomes were generally severe with 6 patients 
jaundiced and hospitalized, 3 developing acute liver failure, and 2 requiring emergency liver 
transplantation. Six of the 7 patients had taken OxyELITE Pro in mid-to-late 2013 which 
was the period that the reformulated Super Thermo formulation of OxyELITE Pro had been 
marketed and distributed. In all cases, the daily dose of OxyELITE Pro ingested was within 
the recommendations from the manufacturer. Interestingly, 3 patients had taken other 
OxyELITE Pro formulations without adverse consequences in the past, prior to 2013. 
Indeed, the long latency to onset in 2 patients (Case #4 and #5) may have been the result of 
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taking OxyELITE Pro produced before 2013, when the constituents did not include aegeline 
and switching to the reformulated product in 2013. Evaluation for competing causes of liver 
injury was unrevealing in all except Case #7 who presumably had pre-existing chronic HBV 
infection.
The histological pattern of liver injury from 4 cases was compatible with other reports of 
toxin or drug mediated liver injury. Submassive hepatic necrosis is usually due to drugs and 
or ischemia. In these cases, the pattern of necrosis and inflammation was not compatible 
with an ischemic etiology. In contrast to cases of acute liver failure ascribed to autoimmune 
hepatitis, there were no lymphoid aggregates and the infiltrate was not rich in plasma cells 
(16). Similarly, a mixed pattern of hepatitis and cholestatic features as noted in Case #1 is 
typical of drug hepatotoxicity and is not characteristic of autoimmune hepatitis (15,17). 
While 4 of the patients described here had detectable autoantibodies at the onset of illness, 
liver histology was generally not consistent with autoimmune hepatitis. In addition, none 
had evidence of hypergammaglobulinemia at presentation nor during follow-up, and 4 of the 
5 who survived without liver transplantation had normal liver enzymes in follow-up and 
were never treated with corticosteroids. Thus, the presence of low and moderate 
autoantibody reactivity in these patients was probably due to the severity of the acute liver 
injury rather than as an indication of autoimmune liver disease.
OxyELITE Pro is a product that contains a number of vitamins, herbs, and other 
micronutrients and compounds. The Super Thermo OxyELITE Pro product was 
reformulated in April 2013, at the request of the US FDA, to remove the ingredient 1,3-
dimethylamylamine (DMAA), which had been linked to cardiovascular toxicity (8,18). 
Chemical analysis of the Super Thermo formulation of OxyELITE Pro linked to cases of 
hepatotoxicity has demonstrated the presence of aegeline (N-(2-hydroxy-2(4-
methoxyphenyl)ethyl)-3-phenyl-2-propenamide). This compound can be extracted from 
Aegle marmelos (bael leafs) which has a long history of use in Ayurvedic medicine to 
improve “energy levels”. It has been alleged that the aegeline in the Super Thermo 
formulation of OxyELITE Pro was chemically synthesized, and the possibility exists that the 
product included metabolic intermediates or was a racemic mixture with one isomer having 
hepatotoxic potential (19). Although rare published reports have suggested occasional 
adverse effects from aegeline consumption, the mechanism by which aegeline and/or other 
components of OxyELITE Pro might mediate liver damage is unknown. OxyELITE Pro also 
contains green tea extract,which has been linked to recent reports of severe hepatotoxicity in 
humans (20,21). However, the amount of green tea extract is limited and there was no 
apparent relationship between the daily dose of OxyELITE Pro taken and severity of liver 
injury, either in this series or in those reported by the CDC or by observers in Honolulu. 
Nonetheless, recent weight loss could lower the threshold for inadvertent liver toxicity from 
catechins in green tea extract as was recently demonstrated in animal studies (4, 22,23).
The US FDA enjoined USP Labs to cease marketing and distribution of the SuperThermo 
formulation of OxyELITE Pro in October 2013 because it contained a new dietary 
ingredient, aegeline, for which the manufacturer had not provided evidence of safety, and 
this formulation was withdrawn from the marketplace shortly thereafter.
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When comparing our cases with the published information on the 29 cases from Hawaii in 
2013, several common features are obvious (7). Firstly, the median age of the patients was 
similar (36 vs 33 years) and there was an over-representation of individuals of east Asian 
descent compared to the general US population (43% and 80% vs 5.5%) raising the 
possibility of a genetic predilection to hepatotoxicity from this HDS product, as has been 
reported with other drugs (24, 25). In addition, most patients presented with severe acute 
hepatocellular injury after several months of OxyELITE Pro ingestion and all but one patient 
in the current series presented between April and November 2013 (Table 1). However, all of 
the DILIN cases occurred in the continental US in comparison to the larger outbreak that 
was reported primarily in Hawaii. An investigation of the Hawaii cases failed to demonstrate 
a common batch or expiration date of the OxyELITE Pro product that was consumed (26). 
The DILIN cases tended to have more severe outcomes, including a higher rate of 
hospitalization (86% vs. 38%) and liver transplant or death (29% vs. 10%), which may relate 
to ascertainment and/or referral bias. Autoimmune features were present in both series, 
although none from the current study had prominent autoimmune features.
Limitations of the current study include the small number of cases limiting the ability to 
identify risk factors for liver injury. In addition, we were not able to obtain a sample of the 
actual OxyELITE Pro formulation ingested for formal chemical analysis of potential 
hepatotoxic ingredients or adulterants as have been found in other HDS products (27). 
Likewise, we could not confirm that the patients were taking the Super Thermo formulation, 
although the timing was suggestive in 6 of the 7 cases. Another potential confounding factor 
was that several of the patients were taking other HDS products that have been associated 
with hepatotoxicity (28–30) but only in Case #1 were these other products thought to be 
even probably related.
The outbreak of severe acute hepatitis due to OxyELITE Pro was striking and led quickly to 
the identification of the responsible agent. At the same time, there has been a gradually 
increasing rate of liver injury from HDS products reported largely due to multi-ingredient 
products similar to OxyELITE Pro that contain multiple vitamins, minerals, nutritional 
elements and herbal products or synthetic compounds. The components of the typical multi-
ingredient dietary supplements often change and their purity and reliability are not well 
documented. These findings stress the importance of considering HDS products in assessing 
acute liver injury of unknown cause, reporting such incidents (to Medwatch if possible) and 
attempting to obtain the suspect product for chemical analysis. These findings also indicate a 
need for enhanced regulatory actions in monitoring the commercial availability of these 
widely used weight loss products.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. 
Two cases of OxyELITE Pro-related liver injury demonstrating mild (A&B—Case #3) and 
severe (C&D, case #2) damage. A. Multiple apoptotic hepatocytes are seen in this single 
high-power field (arrowheads). Foci of macrophages and lymphocytes are present in the 
center of the field. (H&E, 600×) B. Portal area showing mild lymphocytic inflammation 
with interface hepatitis. Several eosinophils are seen (arrows). (H&E, 600×) C. Severe acute 
hepatitis with massive parenchymal necrosis. Only a few islands of hepatocytes remain 
(arrowheads). (H&E, 100×) D. Staining for keratin 7 shows ductular reaction in the areas of 
parenchymal loss. (anti-keratin 7 immunostain, 100×).
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Table 2
Comparison of OxyELITE Pro Hepatotoxicity cases from DILIN and the CDC
DILIN Cases
(n=7)
CDC cases
(n=29)
Median (range) age): years 36 (28–62) 33 (16–66)
Time of Onset: Range Aug 2011–Oct 2013 May – Oct 2013
Median (range) duration of OEP use;
days
129 (37, 711) 60
Female sex (%) 6 (86%) 16 (55%)
Asian race (%) 3 (43%) (>80%)
Median (range) peak ALT: U/L 2242(729–8,384) 1793 (347–3,091)
Median (range) peak bilirubin: mg/dL 15 (0.4, 38.3) 12.6 (2.8, 39.6)
Liver biopsy (%) 4 (57%) 10 (34%)
Hospitalized (%) 6 (86 %) 11 (38%)
Liver transplant or death (%) 2 (29%) 3 (10%)
Use of concomitant HDS (%) 5 (71%) 12 (41%)
ALT = Alanine aminotransferase (U/L); HDS = Herbal and Dietary Supplement
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